AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12454299 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical muscle stimulation (TCEMS) of the lower extremities, performed three times a week for 20 minutes each session for six weeks.
Number of subjects: 18
Study 12454299 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group).
Number of subjects: 18
Study 12454299 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical muscle stimulation (TCEMS) of the lower extremities.
Number of subjects: 18
Study 10336003 — intervention group
Group type: EXPERIMENTAL
Intervention: TT virus DNA detection in donors with elevated ALT levels (mean ALT 89.3 U/L)
Number of subjects: 861
Study 10336003 — intervention group
Group type: COMPARATOR
Intervention: TT virus DNA detection in donors with normal ALT levels (<= 45 U/L)
Number of subjects: 861
Study 7487244 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.625 mg
Number of subjects: 65
Study 7487244 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 1.25 mg
Number of subjects: 65
Study 7487244 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 2.5 mg
Number of subjects: 65
Study 7487244 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 5 mg
Number of subjects: 65
Study 7487244 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (all doses)
Number of subjects: 65
Study 1793725 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with electrically stimulated lymphatic drainage (group B)
Number of subjects: 74
Study 1793725 — intervention group
Group type: COMPARATOR
Intervention: Elastic sleeve only (group A)
Number of subjects: 74
Study 7074796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine treatment (4-hour infusions weekly for 24 weeks)
Number of subjects: 26
Study 7074796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26
Study 31816038 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (E) 10 mg with Linagliptin (L) 5 mg once daily
Number of subjects: 97
Study 31816038 — intervention group
Group type: COMPARATOR
Intervention: Metformin (M) 850 or 1000 mg twice daily with Insulin Glargine (I) once daily
Number of subjects: 97
Study 29787937 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training using the CogMed program (20 to 25 computerised 25-min sessions over 5-7 weeks)
Number of subjects: 452
Study 29787937 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 452
Study 27268312 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel use within 5 days of surgery
Number of subjects: 79
Study 27268312 — intervention group
Group type: EXPERIMENTAL
Intervention: PRU <170
Number of subjects: 79
Study 27268312 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel users
Number of subjects: 79
Study 24368640 — intervention group
Group type: EXPERIMENTAL
Intervention: Open dissection tunnel EVH device
Number of subjects: 1549
Study 24368640 — intervention group
Group type: COMPARATOR
Intervention: Closed dissection tunnel EVH device
Number of subjects: 1549
Study 24030269 — intervention group
Group type: COMPARATOR
Intervention: Quality Improvement Intervention at Health Centres (FI)
Number of subjects: 14576
Study 24030269 — intervention group
Group type: COMPARATOR
Intervention: Community Intervention (CI)
Number of subjects: 14576
Study 24030269 — intervention group
Group type: COMPARATOR
Intervention: Combined Intervention (FI + CI)
Number of subjects: 14576
Study 24030269 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 14576
Study 20578537 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/day for 3 days)
Number of subjects: 67
Study 20578537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 19012623 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% n‐CAP for 50 strokes (2-day use)
Number of subjects: 100
Study 19012623 — intervention group
Group type: EXPERIMENTAL
Intervention: Various concentrations of n‐CAP
Number of subjects: 100
Study 16640806 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (100 mg/m2) and carboplatin (AUC 2) once weekly for 6-8 weeks (arm A)
Number of subjects: 883
Study 16640806 — intervention group
Group type: COMPARATOR
Intervention: Every-3-week paclitaxel (200 mg/m2) and carboplatin (AUC 6) on day 1 every 21 days (arm B)
Number of subjects: 883
Study 12871402 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin + omega-3 fatty acids (1.68 g day(‐1))
Number of subjects: 42
Study 12871402 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin + placebo (corn oil)
Number of subjects: 42
Study 12871402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 42
Study 10976127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflated
Number of subjects: 109
Study 10976127 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet not inflated
Number of subjects: 109
Study 8604912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus metronidazole intravenously (CIP/MTZ IV)
Number of subjects: 671
Study 8604912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus metronidazole intravenously and orally (CIP/MTZ IV/PO)
Number of subjects: 671
Study 8604912 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin intravenously (IMI IV)
Number of subjects: 671
Study 8604912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus metronidazole orally (CIP/MTZ IV/PO)
Number of subjects: 671
Study 1415526 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mo rhGH
Number of subjects: 10
Study 1415526 — intervention group
Group type: COMPARATOR
Intervention: 6 mo placebo
Number of subjects: 10
Study 3971104 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous mezlocillin
Number of subjects: 100
Study 3971104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mezlocillin)
Number of subjects: 100
Study 30451243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125%/fentanyl 5.0 μg/mL
Number of subjects: 94
Study 30451243 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2%/fentanyl 5.0 μg/mL
Number of subjects: 94
Study 27982546 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% permethrin cream applied once daily for two consecutive days (group 2)
Number of subjects: 89
Study 27982546 — intervention group
Group type: COMPARATOR
Intervention: 5% permethrin cream applied once daily (group 1)
Number of subjects: 89
Study 26283736 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 20
Study 26283736 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 20
Study 24641640 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transversus abdominis plane analgesia (n = 35)
Number of subjects: 70
Study 24641640 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (n = 35)
Number of subjects: 70
Study 22158697 — intervention group
Group type: EXPERIMENTAL
Intervention: '6D Cards'
Number of subjects: 140
Study 22158697 — intervention group
Group type: COMPARATOR
Intervention: Usual discussion processes (Control)
Number of subjects: 140
Study 20454812 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT parameters in patients with MDR
Number of subjects: 102
Study 20454812 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT parameters in patients without MDR
Number of subjects: 102
Study 20454812 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 102
Study 20454812 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HbA1c, microalbuminuria, cholesterol levels, triglycerides, hypertension prevalence, age at diagnosis, diabetes duration
Number of subjects: 102
Study 17873684 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 44
Study 17873684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15806747 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 11908577 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Fitness Training (HIF)
Number of subjects: 37
Study 11908577 — intervention group
Group type: COMPARATOR
Intervention: Low Intensity Fitness Training (LIF)
Number of subjects: 37
Study 10101739 — intervention group
Group type: EXPERIMENTAL
Intervention: Single i.v. bolus of 50 micrograms GHRH
Number of subjects: 0
Study 10101739 — intervention group
Group type: EXPERIMENTAL
Intervention: Five 'repetitive' boluses of 10 micrograms GHRH
Number of subjects: 0
Study 10101739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8569272 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography (TVU)
Number of subjects: 33
Study 1934418 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 468
Study 1934418 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 468
Study 839327 — intervention group
Group type: COMPARATOR
Intervention: Formula 1 (F1) = 1.5 gm/dl protein, 60 parts bovine whey proteins: 40 parts bovine caseins
Number of subjects: 0
Study 839327 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 2 (F2) = 3.0 gm/dl, 60:40
Number of subjects: 0
Study 839327 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 3 (F3) = 1.5 gm/dl, 18:82
Number of subjects: 0
Study 839327 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 4 (F4) = 3.0 gm/dl, 18:82
Number of subjects: 0
Study 839327 — intervention group
Group type: COMPARATOR
Intervention: Pooled human milk (BM)
Number of subjects: 0
Study 31743617 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 33
Study 31743617 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 33
Study 31743617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 31133627 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on Multi‐Theory Model (MTM)
Number of subjects: 94
Study 31133627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 94
Study 28690144 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative conventional chemoradiotherapy (CRT) with delayed surgery (50Gy/25 fr with fluorouracil and leucovorin on the 1st and 5th week of RT followed by TME surgery in 6-8 weeks and 4 cycles of adjuvant fluorouracil/leucovorin every 4 weeks)
Number of subjects: 150
Study 28690144 — intervention group
Group type: COMPARATOR
Intervention: Preoperative short-course radiotherapy (SCRT) with delayed surgery (25Gy/5 fr followed by TME surgery in 6-8 weeks)
Number of subjects: 150
Study 28690144 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative conventional chemoradiotherapy (CRT)
Number of subjects: 150
Study 28690144 — intervention group
Group type: COMPARATOR
Intervention: Preoperative short-course radiotherapy (SCRT)
Number of subjects: 150
Study 28690144 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative conventional chemoradiotherapy (CRT) in intent-to-treat (ITT) population
Number of subjects: 150
Study 28690144 — intervention group
Group type: COMPARATOR
Intervention: Preoperative short-course radiotherapy (SCRT) in intent-to-treat (ITT) population
Number of subjects: 150
Study 24621355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification intervention programme (8 weeks duration)
Number of subjects: 68
Study 24621355 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 68
Study 23796359 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus R0011 1.9×10(9) cfu and Lactobacillus acidophilus R0052 0.1×10(9) cfu)
Number of subjects: 70
Study 23796359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17086775 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral head‐out water immersion (34.5 degrees C)
Number of subjects: 26
Study 15280147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic vaginal gel (Miphil), 2.5 g every 3 days for 12 weeks
Number of subjects: 70
Study 15280147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15280147 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic vaginal gel (Miphil)
Number of subjects: 70
Study 10716137 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 400
Study 10716137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 9361939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg twice a day for the first 10 days, then 250 mg/day for 6 months)
Number of subjects: 80
Study 9361939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9361939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 80
Study 1336892 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg administered as a single daily dose for 3 days)
Number of subjects: 30
Study 1336892 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid (50 mg/kg/day given b.i.d. for 10 days)
Number of subjects: 30
Study 3987546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous felodipine
Number of subjects: 0
Study 3987546 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral felodipine (0.10 mg/kg)
Number of subjects: 0
Study 3987546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral felodipine (0.01 mg/kg)
Number of subjects: 0
Study 3987546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3987546 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (placebo comparison)
Number of subjects: 0
Study 3987546 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive patients (placebo comparison)
Number of subjects: 0
Study 31993993 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary anastomosis
Number of subjects: 0
Study 31993993 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's procedure
Number of subjects: 0
Study 31993993 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoidectomy
Number of subjects: 0
Study 30277930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylnaltrexone
Number of subjects: 22
Study 30277930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30277930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 27859410 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 127
Study 27859410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 26024831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 0
Study 26024831 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 0
Study 24419299 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI
Number of subjects: 38
Study 24419299 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI (more overweight group, n = 19; BMI 27.5-30 kg/m²)
Number of subjects: 38
Study 21978432 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular human dermal matrix augmentation (GraftJacket)
Number of subjects: 42
Study 21978432 — intervention group
Group type: COMPARATOR
Intervention: No augmentation
Number of subjects: 42
Study 19465231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control
Number of subjects: 33040
Study 17967640 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg/kg
Number of subjects: 90
Study 17967640 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 90
Study 12972442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume/moderate-intensity group (approximately 12 miles walking/wk at 40-55% peak O2 consumption)
Number of subjects: 154
Study 12972442 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume/high-intensity group (approximately 20 miles jogging/wk at 65-80% peak O2 consumption)
Number of subjects: 154
Study 12972442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume/high-intensity group (approximately 12 miles jogging/wk at 65-80% peak O2 consumption)
Number of subjects: 154
Study 12972442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study 11591187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once daily
Number of subjects: 10
Study 11591187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9624757 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8089543 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (40 mg orally four times a day)
Number of subjects: 52
Study 8089543 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg orally three times a day)
Number of subjects: 52
Study 8089543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet orally three times a day)
Number of subjects: 52
Study 2819522 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant cry
Number of subjects: 32
Study 2819522 — intervention group
Group type: COMPARATOR
Intervention: Smoke alarm
Number of subjects: 32
Study 31337371 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0
Study 31337371 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 0
Study 28357673 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 201
Study 28357673 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 201
Study 28357673 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation dataset from Nanfang Hospital (n = 135)
Number of subjects: 201
Study 24168840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 62
Study 24168840 — intervention group
Group type: COMPARATOR
Intervention: Befriending
Number of subjects: 62
Study 24168840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy Scale (CTS)
Number of subjects: 62
Study 24168840 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE Treatment Integrity Measure (ATIM)
Number of subjects: 62
Study 22644743 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 50
Study 22644743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 50
Study 22644743 — intervention group
Group type: COMPARATOR
Intervention: Control (pretreatment)
Number of subjects: 50
Study 21703000 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of CRIS measure
Number of subjects: 102
Study 21703000 — intervention group
Group type: COMPARATOR
Intervention: In-person administration of CRIS measure
Number of subjects: 102
Study 17901881 — intervention group
Group type: EXPERIMENTAL
Intervention: logMAR crowded Kay picture test
Number of subjects: 51
Study 17901881 — intervention group
Group type: COMPARATOR
Intervention: crowded logMAR acuity test
Number of subjects: 51
Study 17901881 — intervention group
Group type: EXPERIMENTAL
Intervention: uncrowded logMAR acuity test
Number of subjects: 51
Study 16682309 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (group T) for nine months at 60% of maximal oxygen uptake (VO2)
Number of subjects: 95
Study 16682309 — intervention group
Group type: COMPARATOR
Intervention: No training (group C)
Number of subjects: 95
Study 14996470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 24
Study 14996470 — intervention group
Group type: COMPARATOR
Intervention: Non-Aspirin
Number of subjects: 24
Study 11555764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized topical saline‐tobramycin solution administered thrice daily for 4 weeks
Number of subjects: 20
Study 11555764 — intervention group
Group type: COMPARATOR
Intervention: Saline‐only solution administered thrice daily for 4 weeks
Number of subjects: 20
Study 9402446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering drugs (mostly simvastatin at an average dose of 14 mg/day)
Number of subjects: 785
Study 9402446 — intervention group
Group type: COMPARATOR
Intervention: No cholesterol lowering drugs (non-users)
Number of subjects: 785
Study 8517380 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 24187
Study 8517380 — intervention group
Group type: COMPARATOR
Intervention: Control (no thrombolytic agents)
Number of subjects: 24187
Study 3327930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (0.06 mg/min)
Number of subjects: 8
Study 3327930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 3327930 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg i.v.)
Number of subjects: 8
Study 28764618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 20
Study 28764618 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study 27079993 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatrists' ability to provide mental health services
Number of subjects: 1099
Study 27079993 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatrists' ability to provide inpatient and other treatments
Number of subjects: 1099
Study 27079993 — intervention group
Group type: EXPERIMENTAL
Intervention: Time during patient visits
Number of subjects: 1099
Study 27079993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient visits to meet clinical needs
Number of subjects: 1099
Study 25467772 — intervention group
Group type: EXPERIMENTAL
Intervention: Community paramedic intervention (regular home visits, health assessments, evidence-based treatments)
Number of subjects: 0
Study 25467772 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 25467772 — intervention group
Group type: EXPERIMENTAL
Intervention: Community paramedic intervention
Number of subjects: 0
Study 22183059 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA, 10 U
Number of subjects: 90
Study 22183059 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA, 30 U
Number of subjects: 90